Humacyte (HUMA) EBITDA (2020 - 2026)

Humacyte (HUMA) has reported EBITDA for 7 consecutive years, with -$27.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 9.19% year-over-year to -$27.0 million in Q2 2026; TTM through Jun 2026 was -$111.2 million, a 0.08% change from a year earlier, with the FY2025 full-year figure at -$108.1 million, up 5.47% from the prior year.
• EBITDA was -$27.0 million for Q2 2026 at Humacyte, up from -$28.9 million in the prior quarter.
• Over five years, EBITDA peaked at -$18.5 million in Q2 2022 and troughed at -$30.8 million in Q4 2025.
• A 5-year average of -$25.7 million and a median of -$26.4 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA tumbled 44.25% in 2023 and advanced 19.33% in 2025, its largest moves.
• Over 5 years, EBITDA stood at -$20.8 million in 2022, then fell by 25.71% to -$26.1 million in 2023, then slipped by 7.43% to -$28.1 million in 2024, then dropped by 9.78% to -$30.8 million in 2025, then climbed by 12.45% to -$27.0 million in 2026.
• The last three EBITDA figures came in at -$27.0 million (Q2 2026), -$28.9 million (Q1 2026), and -$30.8 million (Q4 2025), per Business Quant data.